Table 1 Patients characteristics (n = 44).

From: Effects of β2-receptor stimulation by indacaterol in chronic heart failure treated with selective or non-selective β-blockers: a randomized trial

Variable

 

Mean ± SD n/%

Age (years)

 

66.04 ± 9.61

Gender (Males N/%)

 

31/70%

Smoking habit

No smokers (N/%)

17/39%

Former smokers (N/%)

27/61%

Rhythm

Sinus rhythm (N/%)

37/84%

Atrial fibrillation (N/%)

7/16%

Mitral regurgitation

Mitral regurgitation absent (N/%)

15/34%

Mitral regurgitation mild (N/%)

19/43%

Mitral regurgitation moderate (N/%)

9/21%

Mitral regurgitation severe (N/%)

1/2%

Drugs

ACE inhibitors (N/%) No

17/39%

ACE inhibitors (N/%) Yes

27/61%

ATII blockers (N/%): No

32/73%

ATII blockers (N/%): Yes

12/27%

Diuretics (N/%) No

8/18%

Diuretics (N/%) Yes

36/82%

Antialdosteronics (N/%) No

10/23%

Antialdosteronics (N/%) Yes

34/77%

Digitalis (N/%) No

41/93%

Digitalis (N/%) Yes

3/7%

Systolic Arterial Pressure (mmHg)

 

123 ± 17

Diastolic Arterial Pressure (mmHg)

 

76 ± 8

Aetilogy: ischemic

23/52%

Aetilogy: idiopathic

19/43%

Aetilogy: other

2/5%

Body mass index

 

28.1 ± 4.6

Left Ventricular Ejection Fraction (%)

 

33.3 ± 5.7

Rest heart rate (bpm)

 

66 ± 10

Haemoglobin (g/dl)

 

13.8 ± 1.3

BNP (pg/ml)

 

291.3 ± 249.5

MDRD (ml/min/1.73 mq)

 

71.8 ± 21.0

NYHA class

NYHA class I

7/16%

NYHA class II

31/70%

NYHA class III

6/14%

MLWHFQ Score

 

28.4 ± 20.0

FEV1 (L/min)/(% predicted value)

 

2.34 ± 0.71/84.5 ± 14.0

VC (L)/(% predicted value)

 

3.28 ± 0.95/91.9 ± 14.1

DLco (ml/min/mmHg)

 

19.91 ± 6.13

Peak VO2 (ml/Kg/min)

 

14.6 ± 3.6

  1. NYHA = NewYork Heart Association; BNP = Brain Natriuretic Peptide; MDRD = estimation of glomerular filtration rate by modification of diet in renal disease formula; FEV1 = Forced Expiratory Volume in 1 second; VC = Vital Capacity; DLco = Lung diffusion for carbon monoxide; VO2 = Oxygen consumption; MLWHF = Minnesota Living With Heart Failure.